Physician profile
Daniel J Gassert
NPI 1073575403
$8,493.77
in general payments reported to CMS, 2019-2025
36 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $257 · 2021: $799 · 2022: $1,217 · 2023: $1,489 · 2024: $1,861 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,685 · Education: $41.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,685.24 |
| Education | $41.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,271.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $921.26 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $826.60 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $742.98 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $352.02 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $338.07 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $311.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $308.06 | 2022-2025 | |
| Gilead Sciences, INC. | $290.57 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $286.47 | 2021-2024 | Dificid, Zerbaxa, Zinplava |
| Pfizer INC. | $254.29 | 2019-2025 | |
| Lilly USA, LLC | $189.46 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $138.39 | 2021-2024 | Injectafer |
| Celgene Corporation | $113.51 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $106.21 | 2024-2025 | Iqirvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $101.63 | 2021-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $98.08 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $97.33 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $96.69 | 2019-2024 | Sutab |
| Pharmacosmos Therapeutics INC. | $92.52 | 2021-2024 | Monoferric |
| Aimmune Therapeutics, INC. | $85.55 | 2024-2025 | Zenpep |
| Enterra Medical, INC. | $82.56 | 2023-2025 | |
| Ardelyx, INC. | $71.61 | 2023-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $50.20 | 2023-2025 | Givlaari |
| Celltrion USA INC. | $41.72 | 2023 | Yuflyma |
| Evoke Pharma, INC. | $41.64 | 2024 | |
| Amgen INC. | $27.49 | 2022 | |
| Redhill Biopharma INC. | $25.11 | 2021 | |
| Ucb, INC. | $20.65 | 2019 | |
| Pentax of America, INC. | $19.90 | 2020 | |
| Pharming Healthcare, INC. | $17.41 | 2021 | |
| Novo Nordisk INC | $17.01 | 2025 | Wegovy |
| Shionogi INC | $14.84 | 2019 | |
| Olympus America INC. | $14.33 | 2021 | |
| Medtronic, INC. | $13.41 | 2021 | |
| Alfasigma USA, INC. | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gassert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.